Government of Telangana signed an MoU with Singapore-based largest engineering firm Surbana Jurong to lay the roadmap for Genome Valley 2.0. Surbana Jurong is reportedly Singapore’s largest engineering firm and one of the largest Asia-based global urban, industrial and infrastructure consulting firms.
Jayesh Ranjan, Principal Secretary, IT & Industries Dept and Nirup Jayanth, Country Head for Jurong Consultants India Pvt. Ltd signed the MoU in the presence of IT Minister KT Rama Rao.
Genome Valley 2.0 is a vision to upgrade the current Genome Valley cluster into a world-class knowledge led integrated corridor in a self-sufficient life sciences ecosystem. The cluster, which currently is an industrial hub is being envisioned to transform into an industry-led, knowledge-based ecosystem to become a driver for local economic development. Additionally, the knowledge economy will foster skill development of the local workforce to an international benchmark, thereby expanding the city’s talent pool.
Surbana Jurong has previously led the planning of the Buena Vista Science exchange that is anchored by the Biopolis industry cluster and situated at the heart of Singapore’s university town, with NUS campus located adjacent to it. The area is also home to new and innovative industrial clusters, specialist research centres such as the CREATE Campus which houses specialist research facilities where leading US universities have set up international collaboration labs for research and development.
In Telangana, the Genome Valley cluster has emerged as the one of the largest life sciences destination in Asia, being home to over 200 companies employing 10,000 people. According to a statement from the minister’s office, the current initiative will introduce a world class knowledge cluster and lay a master plan to transform the ecosystem into a smart satellite town of Hyderabad.
Moreover, the cluster’s proposed footprint expansion will enable more global companies to establish and expand their operations. The cluster is already home to Novartis, GlaxoSmithKline, Mylan, DuPont, US Pharmacopeia among others and has recently witnessed major investments from new as well as existing companies.